
argenx already holds a minority stake in UNP and will acquire all remaining shares

The results for litifilimab support the potential to achieve rapid and durable improvements in skin disease activity

The acquisition is to advance treatments for serious autoimmune and allergic diseases

The real-world findings support the long-term benefits of continuous treatment

The deal expands the company’s rare disease portfolio

The deal includes an approved treatment for acromegaly and other pipeline candidates

Myricx, a UK-based biotech, is developing a new class of antibody-drug conjugates

The move expands Klick’s scientific expertise in oncology and rare diseases

The acquisition will give the company access to a treatment for COPD

The acquisition includes clinical-stage candidates for atopic dermatitis and asthma

The acquisition will expand the company’s immunology pipeline

In the study, there were improvements in motor function as well as a slowing of neurodegeneration